Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.

Gisondi, P

Switching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis. [electronic resource] - The British journal of dermatology 08 2020 - 397-398 p. digital

Publication Type: Journal Article

1365-2133

10.1111/bjd.19013 doi


Antibodies, Monoclonal--therapeutic use
Biosimilar Pharmaceuticals--therapeutic use
Drug Substitution
Humans
Infliximab--therapeutic use
Psoriasis--drug therapy
Treatment Outcome